News Major shareholder announcement – BlackRock, Inc. Staff September 11, 2023 Iframe sync Post navigation Previous: Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Next: Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston More Stories Fitness News UREVO Announces Black Friday Sale 2026 with Its Biggest Discounts of the Year Staff November 18, 2026 News Pharmaceutical Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study Staff November 18, 2026 Cancer Clinical Trial Diagnostics DNA Medicare News Patient Care Pharmaceutical Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026 Staff November 18, 2026